[1]Müller V,Bartsch R,Lin NU,et al.Epidemiology,clinical outcomes,and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases:A systematic literature review.Cancer Tr...
unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2020;180(3):597-609.
近日,山东大学材料学院蒋妍彦团队在Advanced Science(IF=16.8 一区)杂志上发表了题为:“A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer.”的文章,研究团队开发了一个纳米治疗平台,结合了双金属金银空心纳米壳、吡咯替尼和赫赛汀,实现了多...
37.Hamilton,E.et al.Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer(HER2CLIMB):Outcomes by hormone receptor status.Cancer Res.81(Suppl.4),Abstr.PD3-08(2021). 38.Lewis Phillips,G.D.et ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
[6]Arab A.,Yazdian-RobatiR.,BehravanJ. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Arch. Immunol Ther. Exp. 2020;68:2. [7]D’AmatoV.,RaimondoL.,FormisanoL.,etal. Mechanisms oflapatinibresistance in HER2-driven breast cancer. Cancer Treat. Rev. 2015;41:87...
10.Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. ...
a her2-let-7-β2-ar circuit affects prognosis in patients with her2-positive breast cancer:一个her2-let-7 -β2-ar电路影响预后的her2阳性乳腺癌患者 热度: HER2阳性乳腺癌治疗原则 热度: HER2-PositiveBreastCancer CompetitiveMonitoring& StrategicAnalysis ...
HER2-Positive Breast Cancer In about 20% of breast cancers, the cells make too much of a protein known as HER2. These cancers tend to be aggressive and fast-growing. For women with HER2-positive breast cancers, the targeted drugtrastuzumab(Herceptin) has been shown to dramatically reduce the...
8、A.M.Starzer,et al.Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan:Secondary endpoint analysis of the prospective single-arm phase II...